The reason I am not selling this stock. I think this is more important than the US market and Altria's investment. I think this could push the stock above $ 20 by Q1 2022. Of course it's just an opinion, I don't have a crystal ball to know.
"Yeah. Yeah, we currently expect to achieve commercialization by the third quarter of 2021. And we're -- as you said, we -- as I said in my opening remarks, we really are prioritizing the rare cannabinoids because we believe that's going to be a greater ability to innovate and provide consumers with differentiated products. And so, we're really excited about that.
I don't want to go on the exact products right now, but we're well on our way. So, again, we are on track, and we're feeling very good about it. And obviously, the rare cannabinoids offer some really unique differentiated consumer products and benefits that we obviously want to focus on."
News 
Market Data 
Discover 
